Literature DB >> 29705939

Macroscopic serosal invasion and small tumor size as independent prognostic factors in stage IIA colon cancer.

Soo Young Lee1, Chang Hyun Kim1, Young Jin Kim1, Hyeong Rok Kim2.   

Abstract

BACKGROUND: This study aimed to investigate the prognostic factors of patients with stage IIA (T3N0M0) colon cancer in terms of macroscopic serosal invasion and small tumor size.
METHODS: We enrolled 375 stage IIA colon cancer patients who underwent curative resection between January 2004 and December 2011. Macroscopic serosal invasion was defined as tumor nodules or colloid changes protruding the surface of the serosa. The clinicopathologic characteristics were analyzed to identify independent prognostic factors.
RESULTS: The median follow-up was 47 months (range, 1-90 months). On multivariate survival analysis, macroscopic serosal invasion (adjusted hazard ratio [HR] = 4.750; p = 0.013), tumor size < 5 cm (adjusted HR = 3.112, p = 0.009), perineural invasion (adjusted HR = 3.528; p = 0.002), < 12 retrieved lymph nodes (adjusted HR = 4.257; p = 0.002), and localized perforation (adjusted HR = 7.666; p = 0.008) were independent risk factors for recurrence.
CONCLUSION: We found novel prognostic factors of stage IIA colon cancer, including macroscopic serosal invasion and small tumor size (< 5 cm). Further studies are needed to evaluate the benefit of adjuvant chemotherapy in patients with these prognostic factors.

Entities:  

Keywords:  Colon cancer; Prognosis; Recurrence

Mesh:

Year:  2018        PMID: 29705939     DOI: 10.1007/s00384-018-3048-0

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  11 in total

1.  Unfavorable effect of small tumor size on cause-specific survival in stage IIA colon cancer, a SEER-based study.

Authors:  Yuwei Wang; Changhua Zhuo; Debing Shi; Hongtu Zheng; Ye Xu; Weilie Gu; Sanjun Cai; Guoxiang Cai
Journal:  Int J Colorectal Dis       Date:  2014-11-13       Impact factor: 2.571

2.  Prognostic Subgroups among Patients with Stage II Colon Cancer.

Authors:  C Richard Boland; Ajay Goel
Journal:  N Engl J Med       Date:  2016-01-21       Impact factor: 91.245

3.  ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.

Authors:  H J Schmoll; E Van Cutsem; A Stein; V Valentini; B Glimelius; K Haustermans; B Nordlinger; C J van de Velde; J Balmana; J Regula; I D Nagtegaal; R G Beets-Tan; D Arnold; F Ciardiello; P Hoff; D Kerr; C H Köhne; R Labianca; T Price; W Scheithauer; A Sobrero; J Tabernero; D Aderka; S Barroso; G Bodoky; J Y Douillard; H El Ghazaly; J Gallardo; A Garin; R Glynne-Jones; K Jordan; A Meshcheryakov; D Papamichail; P Pfeiffer; I Souglakos; S Turhal; A Cervantes
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

4.  Tumor size predicts long-term survival in colon cancer: an analysis of the National Cancer Data Base.

Authors:  Sukamal Saha; Mohammed Shaik; Gregory Johnston; Supriya Kumar Saha; Lindsay Berbiglia; Micheal Hicks; Jill Gernand; Sandeep Grewal; Madan Arora; David Wiese
Journal:  Am J Surg       Date:  2014-12-23       Impact factor: 2.565

Review 5.  Adjuvant therapy for stage II colon cancer: an elephant in the living room?

Authors:  A Zaniboni; R Labianca
Journal:  Ann Oncol       Date:  2004-09       Impact factor: 32.976

6.  Tumor size is associated with the systemic inflammatory response but not survival in patients with primary operable colorectal cancer.

Authors:  Joseph Em Crozier; Donald C McMillan; Colin S McArdle; Wilson J Angerson; John H Anderson; Paul G Horgan; Ruth F McKee
Journal:  J Gastroenterol Hepatol       Date:  2007-12       Impact factor: 4.029

7.  Evaluation and comparison of the clinical, surgical and pathological TNM staging of colorectal cancer.

Authors:  Revekka Harisi; Zsuzsanna Schaff; Lajos Flautner; Tamas Winternitz; Balazs Jaray; Zsuzsanna Nemeth; Peter Kupcsulik; Janos Weltner
Journal:  Hepatogastroenterology       Date:  2008 Jan-Feb

8.  Macroscopic serosal classification of colorectal cancer and its clinical significance.

Authors:  Yong-Peng Wang; Peng-Tao Guo; Zhi Zhu; Hao Zhang; Yan Xu; Si-Ping Ma; Zhen-Ning Wang; Hui-Mian Xu
Journal:  Int J Clin Exp Med       Date:  2015-11-15

9.  Value of tumor size as a prognostic variable in colorectal cancer: a critical reappraisal.

Authors:  Peter Kornprat; Marion J Pollheimer; Richard A Lindtner; Andrea Schlemmer; Peter Rehak; Cord Langner
Journal:  Am J Clin Oncol       Date:  2011-02       Impact factor: 2.339

10.  The integration of macroscopic tumor invasion of adjacent organs into TNM staging system for colorectal cancer.

Authors:  Ji-Wang Liang; Peng Gao; Zhen-Ning Wang; Yong-Xi Song; Ying-Ying Xu; Mei-Xian Wang; Yu-Lan Dong; Hui-Mian Xu
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

View more
  4 in total

1.  Tumor Deposits and Perineural Invasion had Comparable Impacts on the Survival of Patients With Non-metastatic Colorectal Adenocarcinoma: A Population-Based Propensity Score Matching and Competing Risk Analysis.

Authors:  Bin Luo; Xianzhe Chen; Guanfu Cai; Weixian Hu; Yong Li; Junjiang Wang
Journal:  Cancer Control       Date:  2022 Jan-Dec       Impact factor: 3.302

2.  Comparison of Long-Term Oncologic Outcomes Between Surgical T4 and T3 in Patients Diagnosed With Pathologic Stage IIA Right Colon Cancer.

Authors:  Youngbae Jeon; Kug Hyun Nam; Seok Won Choi; Tae Sik Hwang; Jeong-Heum Baek
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

3.  Dysregulated PDGFR alpha expression and novel somatic mutations in colorectal cancer: association to RAS wild type status and tumor size.

Authors:  Nadia Ben Jemii; Haifa Tounsi-Kettiti; Hamza Yaiche; Najla Mezghanni; Amira Jaballah Gabteni; Emna Fehri; Chayma Ben Fayala; Sonia Abdelhak; Samir Boubaker
Journal:  J Transl Med       Date:  2020-11-19       Impact factor: 5.531

Review 4.  Pathological Features and Prognostication in Colorectal Cancer.

Authors:  Kabytto Chen; Geoffrey Collins; Henry Wang; James Wei Tatt Toh
Journal:  Curr Oncol       Date:  2021-12-13       Impact factor: 3.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.